SCHEMBL30376152

SCHEMBL30376152

Cc1cc(C=O)cnc1N1CCC(CN(C)C(=O)OC(C)(C)C)CC1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AOC3 Q16853 1/20 0.36
PIK3CD O00329 1/20 0.35
SIRT2 Q8IXJ6 1/20 0.35
SIRT1 Q96EB6 1/20 0.35
SIRT3 Q9NTG7 1/20 0.35
POLB P06746 1/20 0.34
SPR P35270 1/20 0.34
HTR2C P28335 5/20 0.33
SLC6A4 P31645 5/20 0.33
OPRK1 P41145 2/20 0.33
HTR2A P28223 1/20 0.33
LIMK2 P53671 1/20 0.33
CKS1B P61024 1/20 0.33
SKP1 P63208 1/20 0.33
SKP2 Q13309 1/20 0.33
GPR119 Q8TDV5 4/20 0.32
PIK3CA P42336 1/20 0.32
MTOR P42345 1/20 0.32
PDE10A Q9Y233 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25241176 1.00 AOC3 (0.36) AOC3PIK3CDSIRT2SIRT1SIRT3
SCHEMBL30375913 0.86 ACACB (0.33) AOC3PIK3CDSIRT2SIRT1SIRT3
SCHEMBL30375613 0.86 PIK3CD (0.46) AOC3PIK3CDPOLBSPROPRK1
SCHEMBL25244803 0.85 AOC3 (0.39) AOC3POLBOPRK1PIK3CAMTOR
SCHEMBL30376000 0.85 BCHE (0.35) PIK3CDSIRT2SIRT1SIRT3POLB
SCHEMBL25252014 0.81 MELK (0.37) AOC3OPRK1
SCHEMBL31533249 0.81 MELK (0.37) AOC3OPRK1
SCHEMBL30376168 0.81 CKS1B (0.52) SIRT2SIRT1SIRT3CKS1BSKP1
SCHEMBL30375825 0.78 CKS1B (0.48) OPRK1CKS1BSKP1SKP2PDE10A
SCHEMBL25211358 0.77 EGFR (0.35) AOC3OPRK1PIK3CAMTORPDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612407-B2 Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist BEONE MEDICINES I GMBH (CH) 2026-04-28 US disclosed
EP-3921319-B1 IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST BEIGENE LTD (KY) 2024-03-06 EP disclosed
US-20230167117-A1 IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST BEONE MEDICINES I GMBH (CH) 2023-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167117-A1 IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST TLR7, TLR1, TLR9 AOC3 3263/4885PIK3CD 603/4885SIRT2 670/4885
US-12612407-B2 Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist TLR7, TLR8, TLR1 AOC3 1748/4885PIK3CD 1098/4885SIRT2 1438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.